

# Phylicia A Aaron

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/1275377/publications.pdf>

Version: 2024-02-01

11  
papers

218  
citations

1306789

7  
h-index

1281420

11  
g-index

11  
all docs

11  
docs citations

11  
times ranked

212  
citing authors

#	ARTICLE	IF	CITATIONS
1	Gemogenovatumel-T (Vigil) immunotherapy as maintenance in frontline stage III/IV ovarian cancer (VITAL): a randomised, double-blind, placebo-controlled, phase 2b trial. <i>Lancet Oncology</i> , The, 2020, 21, 1661-1672.	5.1	69
2	The blood-brain barrier internalises <i>Cryptococcus neoformans</i> via the EphA2-tyrosine kinase receptor. <i>Cellular Microbiology</i> , 2018, 20, e12811.	1.1	54
3	Gemogenovatumel-T (Vigil) immunotherapy demonstrates clinical benefit in homologous recombination proficient (HRP) ovarian cancer. <i>Gynecologic Oncology</i> , 2021, 161, 676-680.	0.6	22
4	Long-term follow-up of Phase 2A trial results involving advanced ovarian cancer patients treated with Vigil® in frontline maintenance. <i>Gynecologic Oncology Reports</i> , 2020, 34, 100648.	0.3	15
5	An Antivirulence Approach for Preventing <i>Cryptococcus neoformans</i> from Crossing the Blood-Brain Barrier via Novel Natural Product Inhibitors of a Fungal Metalloprotease. <i>MBio</i> , 2020, 11, .	1.8	13
6	Proof of principle study of sequential combination atezolizumab and Vigil in relapsed ovarian cancer. <i>Cancer Gene Therapy</i> , 2021, , .	2.2	12
7	Harnessing the Activity of the Fungal Metalloprotease, Mpr1, To Promote Crossing of Nanocarriers through the Blood-Brain Barrier. <i>ACS Infectious Diseases</i> , 2020, 6, 138-149.	1.8	9
8	Long-Term Follow-Up of Gemogenovatumel-T (Vigil) Survival and Molecular Signals of Immune Response in Recurrent Ovarian Cancer. <i>Vaccines</i> , 2021, 9, 894.	2.1	9
9	Examination of Fluconazole-Induced Alopecia in an Animal Model and Human Cohort. <i>Antimicrobial Agents and Chemotherapy</i> , 2019, 63, .	1.4	6
10	Vigil: Personalized Immunotherapy Generating Systemic Cytotoxic T Cell Response. <i>Cancer Science &amp; Research</i> , 2020, 3, .	0.2	5
11	Network based analysis identifies TP53m-BRCA1/2wt-homologous recombination proficient (HRP) population with enhanced susceptibility to Vigil immunotherapy. <i>Cancer Gene Therapy</i> , 2022, 29, 993-1000.	2.2	4